Physician profile
Mohammed A Issa
NPI 1871793661
$5,897.94
in general payments reported to CMS, 2019-2025
12 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 82% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $69.14 · 2021: $1,925 · 2022: $538 · 2023: $317 · 2024: $376 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,135 · Consulting Fee: $1,000 · Travel and Lodging: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.51 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $936.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,610.69 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Tyrx |
| Boston Scientific Corporation | $338.84 | 2022-2023 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $220.76 | 2019-2024 | Senza |
| Medtronic USA, INC. | $149.51 | 2019-2020 | |
| Biotronik Nro, INC. | $147.07 | 2024 | Prospera |
| Spr Therapeutics, INC | $141.72 | 2021 | |
| Mml US, INC. | $125.91 | 2022 | |
| Abbott Laboratories | $65.62 | 2019-2021 | |
| Bioventus LLC | $63.77 | 2023-2024 | Stimrouter Implantable Kit, Durolane |
| Abbvie INC. | $16.68 | 2023 | |
| Orexo US, INC. | $11.48 | 2020 | |
| Vertos Medical, INC. | $5.89 | 2024 | Mild Device Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Issa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.